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ABSTRACT 
Objective: To develop and validate High-Performance Thin Layer Chromatography (HPTLC) analytical method for the determination of Duloxetine 
Hydrochloride (DUL) and Methylcobalamin (MEC) in the standard mixture and pharmaceutical capsule dosage form by implementing Quality by the 
Design (QbD) approach. 
Methods: The chromatographic separation was performed on aluminium plates precoated by silica gel 60 F-254 using propanol: water: 25% v/v 
ammonia solution (9:2:1, v/v/v) as a mobile phase which was optimized with the help of a design expert. Densitometric analysis was carried out in 
the absorbance mode at 280 nm. 
Results: Compact spots for Duloxetine HCl and Methylcobalamin were found at retardation factor (Rf
Conclusion: A new, simple, accurate, and precise HPTLC analytical method has been developed and validated for the determination of Duloxetine 
HCl and Methylcobalamin in pharmaceutical capsule dosage form by QbD concept in favour of fewer trials and error-free experimentation for the 
optimization process. The method seems to be suitable for the quality control in the pharmaceutical industry because of its sensitivity, simplicity, 
and selectivity. 
) value of 0.77±0.02 and 0.55±0.03, 
respectively. The linear regression analysis data for the calibration plots showed correlation coefficient 0.9989 and 0.999 with a concentration 
range of 1200-3600 ng/spot and 60-180 ng/spot for Duloxetine HCl and Methylcobalamin respectively. Limit of detection (LOD) and limit of 
quantification (LOQ) was found to be 113.39 and 343.62 ng for Duloxetine HCl and 6.68 and 20.24 ng for Methylcobalamin, respectively. The 
method was validated for precision, accuracy, robustness, LOD and LOQ according to ICH Q2 R1 guidelines. 
Keywords: Duloxetine HCl (DUL), Methylcobalamin (MEC), Quality by Design (QbD), HPTLC, Validation 
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INTRODUCTION 
Quality by design is a systematic approach to development that 
begins with predefined objectives and emphasizes product and 
process understanding and process control, based on sound science 
and quality risk management [1]. Traditional chromatographic 
method development has always involved the time-consuming 
process of varying one system parameter at a time, examining its 
effect on the method and system operation. This generally requires a 
large number of experimental runs and in most situations the 
developed method requires further development [2].  
The objective of the QbD initiative is to demonstrate both 
understanding and control of pharmaceutical processes to deliver 
high-quality pharmaceutical products while affording opportunities 
for continuous improvement. QbD delivers a better understanding of 
method capabilities and limitations; ensures a superior chance of 
successful downstream method validation and transfer. The QbD 
concept can be extended to analytical methods [3]. The analytical 
methods used for the analysis of active pharmaceutical ingredients 
(API) and drug products are an integral part of the QbD. 
Duloxetine HCl (DUL)-(3S)-N-methyl-3-(naphthalen-1-yloxy)-3-
(thiophen-2-yl) propan-1-amine hydrochloride has an empirical 
formula of C18H19
Methylcobalamin (fig. 1(B)) is MeCbl; 
NOS. HCl and a molecular weight of 333.38 g/mol 
(fig. 1(A)) [4]. It is a potent inhibitor of serotonin and 
norepinephrine reuptake and thus it is used for major depressive 
disorders [5-7], anxiety disorder, and pain associated with diabetic 
peripheral neuropathy or fibromyalgia. Furthermore, it provides 
evidence of an effect on pain in the case of urinary incontinence [8, 
9] independent of its effect on depression. Therefore, Duloxetine HCl 
is used in the treatment of the different symptoms of depression [10]. 
Coα-[α-(5,6-dimethylbenz-1H-
imidazolyl)]-Co β methylcobamide and has an empirical formula 
C63H91CoN13O14P. It is a cobalamin, and it is a form of Vitamin B12. 
Vitamin B12
The methionine synthase is an enzyme responsible for the 
conversion of the amino acid homocysteine into methionine and this 
enzyme requires Methylcobalamin as a cofactor. Methylcobalamin is 
also used in the treatment of peripheral neuropathy, diabetic 
neuropathy, hearing loss, Alzheimer’s disease and as a preliminary 
treatment for amyotrophic lateral sclerosis [11]. 
 is used in the body in two forms such as 
Methylcobalamin and 5-deoxyadenosyl cobalamin.  
 
 
Fig. 1: Chemical structure of duloxetine hydrochloride (A) and 
methylcobalamin (B) 
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The combined dosage form of these drugs is used for the treatment 
of neuropathic pain associated with peripheral neuropathy 
especially diabetic neuropathy. Duloxetine HCl is not official in any 
pharmacopoeia. Methylcobalamin is official in Japanese Pharmacopoeia 
[12]. The combination of these two drugs is not official in any 
pharmacopoeia; hence, no official method is available for the 
simultaneous estimation of Duloxetine HCl and Methylcobalamin in their 
combined dosage forms. A literature survey indicated few analytical 
methods like Spectrofluorimetric method [13], gas chromatography [14], 
MS, NMR spectrometry, and X-ray analysis [15, 16], HPLC and HPTLC 
methods [17-32], UV Spectrophotometric method [33-41] and capillary 
electrophoresis with laser-induced fluorescence detection method [42] 
which have been reported for the determination of DUL and MEC in 
individual or combination with other drugs in pharmaceutical dosage 
form and in biological samples. This paper aims to describe the 
development and validation of new, simple and robust HPTLC method 
for the simultaneous determination of Duloxetine HCl and 
Methylcobalamin in standard and in its pharmaceutical dosage form by 
implementing the Quality by Design approach.  
MATERIALS AND METHODS 
Reagents and materials 
Duloxetine HCl (DUL) and Methylcobalamin (MEC) were 
procured as gratis samples from Sunrise Pharma Pvt Ltd (Satej, 
Ahmedabad, India). Capsule formulation, Duzela®
The slit dimension was kept at 5 mm × 0.45 mm and 20 mm/s 
scanning speed was employed. The mobile phase consisted of 
propanol: water: 25% v/v strong ammonia solution (9:2:1, v/v/v). 
Linear ascending development was carried out in 20 cm × 10 cm 
twin trough glass chamber saturated with the mobile phase to a 
distance of 85 mm. The optimized chamber saturation time for the 
mobile phase was 15 min at room temperature (25±2 °C) and at a 
relative humidity of 55±5 % RH. Subsequent to the development, 
TLC plates were dried in a current of air with the help of an air-
dryer. Densitometric scanning performed on Camag TLC scanner 
III in the absorbance mode was scanned in the range of 200-300 
and select the optimised wavelength at 280 nm. The source of 
radiation utilized was a deuterium lamp. The evaluation was done 
using linear regression analysis via peak areas. 
 M 30 (Sun 
Pharma laboratories ltd., India), was obtained commercially with 
the labelled amounts of 30 mg of DUL and 1.5 mg of MEC. 
Analytical reagents propanol and strong ammonia were 
purchased from Merck, Mumbai, India. HPLC grade methanol 
was purchased from Finar Chemicals Ltd., Ahmedabad, India. 
HPLC grade water was purchased from Rankem, Ankleshwar, 
India. Aluminium-backed silica gel 60 F-254 plates (#1.05554, 
20 cm × 10 cm: 200 μm thickness) were purchased from E. 
Merck (Darmstadt, Germany). 
Equipment and chromatographic conditions 
Chromatographic separation of the drugs was performed by a 
CAMAG HPTLC system equipped with Linomat V autosampler, TLC 
scanner III with winCATS 1.2.2 software (CAMAG, Muttenz, 
Switzerland). The prepared dilution of standards was spotted in the 
form of bands of width 6 mm with a Hamilton 100 microliter 
syringe, Camag on pre-coated silica gel aluminium Plates 60F-254 
(20 cm × 10 cm, 200 μm thickness, Merck, Darmstadt, Germany) 
using a Linomat V sample applicator. The plates were prewashed by 
methanol and activated at 60 °C for 2.5 min prior to 
chromatography. A constant application rate 150 nl/s was employed 
and the space between the two bands was 12 mm.  
Method development 
Based on sample solubility, pKa value, and solvent polarity, various 
mobile phase compositions were tried to get a good separation. The 
standard solution containing a mixture of DUL and MEC as well as 
individual drugs were run in different mobile phases in order to find 
the best conditions for separating both the drugs simultaneously. 
The composition of mobile phase for separation was determined to 
be propanol: water: 25% v/v ammonia solution. For quantitative 
analytical purposes, the wavelength was set at 280 nm as the 
optimum wavelength. 
Solution preparation 
Preparation of standard solution  
A standard stock solution mixture was prepared in methanol 
containing 3000 μg/ml of DUL and 150 μg/ml of MEC. Pipette out 1 
ml from standard stock solution into a 10 ml volumetric flask and 
makeup with methanol to get the working standard solution 
containing 300 ng/µl of DUL and 15 ng/µl of MEC.  
Preparation of sample solution  
Take twenty capsules, powdered the inner contents to fine powder 
(each capsule containing 30 mg of DUL and 1.5 mg of MEC). Weigh 
and transfer equivalent to 300 mg of DUL and 15 mg of MEC into a 
100 ml volumetric flask. Add 60 ml methanol in a volumetric flask 
and sonicate for 30 min with intermediate shaking. Make up volume 
with methanol up to 100 ml and prepared stock solution containing 
3000 μg/ml of DUL and 150 μg/ml of MEC. Pipette out 1 ml from 
sample stock solution into a 10 ml volumetric flask and makeup with 
methanol to get the working sample solution containing 300 ng/µl of 
DUL and 15 ng/µl of MEC.  
Software aided method optimization 
Response surface methodologies, such as the Box-Behnken and 
Central Composite Design (CCD), were the models possible 
curvature in the response. Central Composite Design, statistical 
screening design, was used to optimize the compositional parameters 
and to evaluate interaction effects and quadratic effects of the 
chromatographic conditions like the mobile phase composition and 
saturation time on retardation factor (Rf
Where, Y is the measured response retardation factor (R
). A response surface design is 
suitable for exploring quadratic response surfaces and constructing 
polynomial models with Design Expert_ (Version 7.0.0.1, Stat-Ease Inc., 
Minneapolis, MN, USA) statistical software [43, 44]. The selection of 
critical factors and ranges examined for optimization was based on 
preliminary univariate studies of method development and 
chromatographic intuition. The Central Composite design matrix 
comprising of 13 experimental runs was constructed. The non-linear 
computer generated quadratic model is given as 
Y = β0 + β1X1 + β2X2 + β12X1X2 + β11X12 + β22X22 + ε 
f) 
associated with each factor level combinations; mobile phase 
composition (water content) (X1) and saturation time (X2). The 
composition of the mobile phase refers to the volume of water with 
respect to the total volume of the mobile phase. The dependent and 
independent variables selected are shown in table 1 along with their 
low, medium (nominal value) and high levels, which were selected 
based on the results from preliminary experimentation. The nominal 
value for two factors, X1  and X2  were 2 ml and 20 min, respectively. 
Accordingly, the water content (X1) was maintained between 1.5 ml 
and 2.5 ml. Similarly, the low and high values of the chamber 
saturation time (X2
 
) were fixed at 15 min and 25 min, respectively.
Table 1: Variables selected in central composite design 
Factor-independent variables Levels used 
Low (-1) Medium (0) High (+1) 
X1 1.5  = Water content (ml) 2.0 2.5 




(retardation factor of DUL) 
2 
Constraints 
(retardation factor of MEC) 
0.68 ≤ Y1
0.51 ≤ Y
 ≥ 0.80 
2 ≥ 0.58 
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A total of thirteen experiments with five centre points were 
conducted by selecting two factors; the water content in the mobile 
phase (X1), the chamber saturation time (X2) and the Rf
The significance of the relevant factors was calculated using Fisher’s 
statistical test for the Analysis of Variance (ANOVA) model. The 
significance of the model was examined using a lack of fit test, p-
value and the model F-value. ANOVA for non-linear regression was 
partitioned the total variation of a sample into components. These 
components were then used to compute an F-ratio that evaluated 
the effectiveness of the model. If the probability associated with the 
F-ratio is low, the model is considered a better statistical fit for the 
data. All experiments were conducted in a randomized order to 
minimize the bias effects of uncontrolled variables. 
 of DUL and 
MEC were the responses selected for both drugs depicted in table 2. 
Replicates (n = 5) of the centre points were performed to estimate 
the experimental error. The adequacy of the model was confirmed 
by considering R-square value of regression analysis, standard 
deviation (SD), predicted residual sum of square (PRESS) and 
coefficient of variance (% CV). 
Statistical analysis of model by analysis of variance (ANOVA) 
Calibration curve of duloxetine HCl and methylcobalamin 
A working standard mixture solution was prepared in methanol 
containing 300 μg/ml of DUL and 15 μg/ml of MEC. Different 
volumes of working standard solution ranging from 4, 6, 8, 10 and 
12 μl were spotted on the TLC plate (10 cm × 10 cm) to obtain 
concentrations of 1200, 1800, 2400, 3000 and 3600 ng/spot of DUL 
and 60, 90, 120, 150 and 180 ng/spot of MEC, respectively. Each 
concentration was spotted five times on the TLC plate. The data of 
peak areas plotted against the corresponding concentrations were 
treated by linear least-square regression analysis. 
 
Table 2: Observed responses in central composite design for 13 analytical trials 
Run Independent variable Dependent variable 
Water content (X1 Saturation time (X) (ml) 2 R) (min) f  (DUL) (Y1 R) f  (MEC) (Y2) 
1 2.50 25 0.74 0.58 
2 2.50 20 0.69 0.57 
3 2.00 25 0.78 0.55 
4 1.50 20 0.79 0.52 
5 2.00 15 0.75 0.54 
6 2.00 20 0.77 0.55 
7 2.00 20 0.76 0.55 
8 1.50 15 0.80 0.51 
9 2.00 20 0.77 0.55 
10 2.00 20 0.76 0.55 
11 2.50 15 0.68 0.54 
12 1.50 25 0.80 0.53 
13 2.00 20 0.77 0.55 
Rf 
 
= Retardation factor 
Method validation 
The analytical method was validated for precision, accuracy, limit of 
detection (LOD), limit of quantification (LOQ) and robustness in 
accordance with ICH guidelines [45]. 
Precision 
Intraday and Interday precision study of DUL and MEC was carried 
out by estimating corresponding responses 3 concentrations and 6 
replicates on the same day and on 3 different days for the 
concentration covering the specified range of Duloxetine HCl (1500, 
3000, 4500 ng/spot) and Methylcobalamin (75, 150, 225 ng/spot).  
Accuracy, as recovery 
Accuracy was evaluated in triplicate, at three different 
concentrations equivalent by spiking to 80, 100, and 120% of the 
active ingredient, by adding a known amount of DUL and MEC 
standard to a sample of known concentration and calculating the 
recovery of DUL and MEC, and % RSD for each concentration. The 
previously analyzed samples (3 μg for DUL and 0.15 μg for MEC) 
were spiked with extra concentration levels of 2.4, 3.0 and 3.6 μg for 
DUL and 1.2, 1.5 and 1.8 μg for MEC and the mixtures were 
reanalyzed by the developed Method. The recovery studies were 
carried out in triplicates each level.  
Limits of detection (LOD) and limit of quantification (LOQ) 
Limit of Detection (LOD) is the lowest concentration in a sample that 
can be detected but not necessarily quantified under the stated 
experimental conditions. The limit of quantitation (LOQ) is the 
lowest concentration of an analyte in a sample that can be 
determined with acceptable precision and accuracy. The LOD and 
LOQ were calculated using the equations as per ICH guideline.  
LOD = 3.3 × ( 𝑆𝑆𝑆𝑆𝑆𝑆⁄ ) 
LOQ = 10 × (𝑆𝑆𝑆𝑆𝑆𝑆⁄ ) 
Where, SD is standard deviation of the peak area (n=5), taken as 
measure of the noise and S is the slope of the corresponding 
calibration curve.  
Robustness  
The robustness of the method was investigated by making small 
deliberate changes in the chromatographic conditions at two 
different levels. The deliberate changes for selected 
chromatographic conditions were different compositions of the 
mobile phase e. g. propanol: water: 25% v/v ammonia solution 
(9.5:1.5:1.0, 9.0:2.0:1.0 and 8.5:2.5:1.0 v/v/v) and chamber 
saturation time (15, 20 and 25 min).  
Analysis of the marketed formulation 
Weigh and determine the average weight of twenty capsules 
contents (Duzela®
RESULTS AND DISCUSSION 
 M 30; label claim 30 mg DUL and 1.5 mg MEC) 
without shell. A portion of crushed powder contents equivalent to 
the weight of one capsule was accurately dissolved in methanol and 
sonicate for 20 min to achieve complete dissolution of DUL and MEC. 
Dilution was done to get a stock solution of DUL (300 ng/μl) and 
MEC (15 ng/μl). The resulting solution was filtered and applied 10 μl 
(3000 ng/spot of DUL and 150 ng/spot of MEC) on TLC plate 
followed by development and scanning. Peak area was measured, 
and % assay was calculated. The response was an average of six 
determinations. 
Selection of wavelength 
The sensitivity of the HPTLC method with ultra-violet detection 
depends on the use of an appropriate wavelength. The developed 
plate was subjected to densitometric measurements in a scanning 
mode in the UV region of 200-400 nm and the overlain spectrum 
was recorded on a CAMAG TLC Scanner 4. Both drugs are 
appreciably absorbed light at 280 nm and this wavelength was 
selected as the detection wavelength (fig. 2). 
Sheladia et al. 








The chromatographic conditions were optimized in order to develop 
an HPTLC method for the simultaneous measurement of DUL and 
MEC in standard and pharmaceutical dosage form. 
Preliminary study 
Various combinations of solvents in different ratios like methanol, 
water, ethyl acetate, chloroform, toluene, ethanol, propanol, diethyl 
ether and 25% v/v strong ammonia solution were tried for resolving 
the peaks of DUL and MEC. Various combinations of propanol and 
water were tried in different ratios as good resolution between two 
drugs was observed. Propanol: water (9:2) gave good resolution, but 
typical peak shape of MEC was lost. Strong ammonia (25% v/v) was 
added to improve peak characteristics. So, the final optimized 
mobile phase, propanol: water: 25% v/v strong ammonia (9:2:1), 
gave highest resolution and Rf  values of 0.77±0.01 and 0.55±0.02 for 
DUL and MEC, respectively (fig. 3) at a fixed chamber saturation time 
of 20 min. The Rf value of both drugs was also minutely affected by 
the chamber saturation time. Therefore, further chromatographic 
conditions were optimized to obtain well-defined, compact bands of 
DUL and MEC with acceptable Rf
CCD was selected due to its flexibility and applied to optimize the 
HPTLC separation by gaining a better understanding of the factor’s 
main and interaction effects. A Response surface-central composite 
statistical experimental design was employed using 13 experimental 
runs that included five centre points. The independent variables 
(such as the water content in the mobile phase (X
 values between 0.2 and 0.8 for both 
drugs using CCD. 
Optimization of chromatographic conditions using CCD 
1) and chamber 
saturation time (X2
 
)) and the responses for all 13 optimized trial 
experimental runs are summarized in table 2. 
 
Fig. 3: Chromatogram of duloxetine HCl (Retardation factor 
(Rf): 0.77) and methylcobalamin (Retardation factor (Rf
 
): 0.55) 
in Standard preparation 
The result of regression analysis (table 3) having low standard 
deviation (SD) values 0.006 and 0.004, higher R-square values 
0.9801 and 0.9596, lower predicted residual sum of square (PRESS) 
values 0.0017 and 0.0016 for Y1  and Y2 ,  respectively indicated an 
excellent adequacy of the regression model. The higher value of 
correlation coefficient (R2) signified an excellent correlation 
between the independent variables. It was observed that the best-
fitted model was the quadratic model. Here, the adjusted R2values 
were reasonable agreement with the predicted value (R2
  
≥0.88) 
which indicated the experimental data fitted regression equations 
well [46]. A coefficient of variation (% CV), a measurement of the 
reproducibility of the model, was less than 10%. An adequate 
precision, a measure of the signal (response) to noise ratio, greater 
than 4 is desirable. The obtained ratio for both drugs (26.445 for 
DUL and 20.111 for MEC) indicated an adequate signal. These 
models can be used to navigate design space. The final equation, in 
terms of the actual components and factors, is shown in table 3. A 
positive value represented an effect that favours optimization, 
whereas a negative value indicated an inverse relationship between 
the factor and the response. 
Table 3: Summary results of regression analysis for quadratic model and responses (Y) 
Response Models Adjusted R Predicted R2 SD 2 PRESS %CV Adequate precision 
Retardation factor of DUL (Y1 Quadratic ) 0.9659 0.8963 0.006 0.0017 0.91 26.445 
Regression equation 𝑌𝑌1 = 0.76 − 0.047𝑋𝑋1 + 0.015𝑋𝑋2 + 0.015𝑋𝑋1𝑋𝑋2 − 0.018𝑋𝑋12 + 0.0067𝑋𝑋22 
Retardation factor of MEC (Y2 Quadratic ) 0.9307 0.8884 0.004 0.0016 0.89 20.111 
Regression equation 𝑌𝑌1 = 0.55 + 0.022𝑋𝑋1 + 0.012𝑋𝑋2 + 0.005𝑋𝑋1𝑋𝑋2 − 0.005𝑋𝑋12 − 0.005𝑋𝑋22 
R2
 
= Correlation coefficient; SD = Standard deviation; PRESS = Predicted residual sum of square; %CV = Coefficient of variance 
The model was also validated with an analysis of variance 
(ANOVA) using the Design Expert software and the results are 
presented in table 4. The model was examined using a lack of fit 
test which indicated an insignificant lack of fit value 
corresponding with a higher p-value as compared to the model 
F-value. From the results of ANOVA (table 4), the Model F-value 
of 68.92 (DUL) and 33.23 (MEC) implied that the model was 
significant.  
 
Table 4: Summary results of ANOVA statistical analysis for models and response (Y-retardation factor) for the finally suggested quadratic model 
Source Sum of Squares Degree of freedom Mean Square F-Value P*-Value 
DUL MEC DUL MEC DUL MEC DUL MEC DUL MEC 
Model 0.016 0.0039 5 5 0.003248 0.000791 68.92 33.23 <0.0001 <0.0001 
Water content 0.013 0.0028 1 1 0.013 0.0028 277.27 118.3 <0.0001 <0.0001 
Saturation time 0.00135 0.00081 1 1 0.00135 0.00081 28.65 34.30 0.0011 0.0006 
Residual 0.000329 0.00016 7 7 0.000047 0.000023 --- --- --- --- 
Lack of fit 0.000209 0.00016 3 3 0.000069 0.000055 2.33 --- 0.2156 --- 
*P–Value (probability)<0.05 indicate model terms are significant. 
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The "Lack of fit F-value" of 2.33 implied the Lack of fit is not 
significant relative to the pure error. There was a 21.56% chance 
that a "Lack of fit F-value" this large could occur due to noise. Non-
significant lack of fit is good to fulfill the fit model requirement. A 
model p-value of <0.0001 indicated that 0.01% chance for large 
“Model F-value” due to noise. P-values less than 0.05 indicated 
model terms were significant [47]. 
Three-dimensional response surface plots and perturbation plots 
were constructed to evaluate the effect of the factors on the 
retardation factor of each drug. Perturbation plots reveal the change 
in response from its nominal value for both drugs with all factors 
held constant at a reference point, and steepest slope or curvature 
indicates sensitiveness to a specific factor. The water content in the 
mobile phase had a most important effect on retardation factor, as 
increasing levels of water content resulted in a decrease in the 
retardation factor of DUL and increased in the retardation factor of 
MEC (fig. 4 (A) and (B)). However, the variation in retardation factor 
due to change in water content of mobile phase was acceptable as an 
evident of a robust method. It was found that a variation in the Rf
 
 
value of DUL and MEC respectively as a function of the water content 
and the chamber saturation time (fig. 5(A) and (B)). The second 
factor, chamber saturation time, had no significant effect on 
retardation factor. 
 
Fig. 4: Perturbation graph showing the effect of factor, A (water content) and B (chamber saturation time), on the Retardation factor (R f) 
of Duloxetine HCl (A) and Retardation factor (R f
 
) of Methylcobalamin (B) 
 
Fig. 5: 3D Response surface plot showing the effect of mobile phase composition (water content) and saturation time on retardation factor 
(Rf) of Duloxetine HCl (A) and retardation factor (Rf
 
) of Methylcobalamin (B) 
In order to get the best chromatographic performance, the 
multicriteria methodology was employed by means of Derringer’s 
desirability function. Individual desirability functions range from 0 
(undesired response) to 1 (fully desired response). A value of D 
close to 1 indicates that combination of different criteria is globally 
optimal. The red area in desirability plot indicates prediction at all 
points in this region is one. The yellow area in overlay plot indicates 
all the constraints are satisfied in this region. Desirability and 
overlay plot were obtained from the model for the selected 
responses (fig. 6 and 7). The agreement between the experimental 
and predicted responses for the predicted optimums, 1 (X1=1.94 ml 
and X2=23.44 min) and 2 (X1=2.37 ml and X2=16.55 min), were 
selected for investigating the predictability of the proposed model. 
In the case of optimum 1, the Rf for DUL was obtained 0.77 for 
experimental and 0.78 for predicted values with % percentage error 
0.09 whereas the Rf  for MEC was obtained 0.54 and 0.55 for 
experimental and predicted values, respectively with % percentage 
error 0.51. In the case of optimum 2, the Rf for DUL was obtained 
0.69 for experimental and 0.70 for predicted values with % 
percentage error 2.01 whereas the Rf  for MEC was obtained 0.54 
and 0.55 for experimental and predicted values, respectively with % 
percentage error 1.90. The percentage of the prediction error was 
calculated using the following formula: predicted error = 
experimental-predicted/predicted × 100. The above results and % 
predicted error identified a set of coordinates that produced a high 
desirability value (D = 1) at optimum condition 1. Thus, these 
coordinates were used to select an optimum experimental condition 
to analyze DUL and MEC in combination. The selected optimized 
condition was propanol: water: ammonia solution (25% v/v) (9:2:1 
v/v/v) as solvent system and 20 min as saturation time showed 
good agreement, resolution with peak area and Rf
  
 values of both 
drugs (0.77±0.02 for DUL; 0.55±0.03 for MEC). 
Sheladia et al. 




Fig. 6: Desirability showing the effect of mobile phase composition (water content) and saturation time on retardation factor of 
Duloxetine HCl and Methylcobalamin 
 
 
Fig. 7: Overlay plot showing the effect of mobile phase composition (water content) and saturation time on retardation factor of 
Duloxetine HCl and Methylcobalamin 
 
Table 5: Linear regression data for calibration curve (n=5) 
Parameters DUL MEC 
Linearity range (ng/spot) 1200-3600 ng/spot 60-180 ng/spot 
Regression equation 𝑌𝑌 = 6.013𝑥𝑥 + 316.4 𝑌𝑌 = 7.553𝑥𝑥 − 1.2 
Correlation coefficient 0.999 0.998 
Slopea) 6.013±0.005 ±SD 7.553±0.020 
Intercepta) 316.40±2.40 ±SD -1.20±2.62 
LOD 113.39 6.68 




The linear regression data for the calibration curves (n=5) as shown 
in table 5 showed a good linear relationship over the concentration 
range of 1200-3600 ng/spot for DUL and 60-180 ng/spot for MEC 
with respect to peak areas. No significant difference was observed in 
the slopes of standard curves. 3D Calibration linearity graph of DUL 
and MEC at 280 nm was obtained (fig. 8). 
Validation of the method 
Precision 
n=5 replicate analysis for each concentration of linearity range; SD = standard deviation 
The repeatability of sample application and measurement of peak 
areas were expressed in terms of relative standard deviation (% 
RSD). The results depicted in table 6 revealed intra-day and inter-
day variation covering the specified range of Duloxetine HCl (1500, 
3000, 4500 ng/spot) and Methylcobalamin (75, 150, 225 ng/spot). 
The low value of the RSD was indicative of the repeatability of the 
method. 
Limit of detection (LOD) and quantification (LOQ) 
LOD and LOQ were estimated using standard deviation (SD) of the 
lowest response and slope of the calibration curve. LOD and LOQ 
were found to be 113.39 ng and 343.62 ng for DUL and 6.68 ng and 
20.24 ng for MEC, respectively. 
Recovery studies 
By spiking previously analyzed test solution 3 μg (DUL) and 0.15 μg 
(MEC) with the additional standard drug, the recovery of the method 
was found to be varied from 98.82 to 100.12% for DUL and from 
98.97 to 100.63% for MEC. Values of % recovery and % RSD were 
listed in table 7. The value of % RSD<2% indicated that the method 
was accurate. 
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Fig. 8: 3D Calibration linearity graph of Duloxetine HCl (1200-3600 ng/spot, Rf at 0.77±0.01); and Methylcobalamin (60-180 ng/spot, Rf
 
 at 
0.55±0.02) at 280 nm 
Table 6: Intra-day and Inter-day precision (n=6) 
Drug Amount 
(ng/spot) 
Intra-day precision Inter-day precision 
Mean %assayb) %RSD ±SD Mean %assayb) %RSD ±SD 
DUL 1500 99.57±0.95 0.95 99.30±1.17 1.18 
3000 99.20±0.72 0.73 99.23±0.72 0.73 
4500 99.35±0.71 0.71 99.18±0.58 0.58 
MEC 75 98.70±0.54 0.54 98.93±0.83 0.84 
150 98.77±0.55 0.56 99.56±0.56 0.56 
225 99.88±1.17 1.17 98.94±1.17 1.18 
b)
 
 n=6 replicate analysis for each interval; SD = standard deviation; RSD = relative standard deviation 
Table 7: Results of recovery studies by standard addition method 
 Amount taken Amount added Total amount recovered (c) Mean % recovery (mean±SD) % RSD 
For DUL 3000 ng 2400 ng 5460.09±48.99 101.11 0.90 
3000 ng 3000 ng 6009.49±34.08 100.16 0.57 
3000 ng 3600 ng 6519.56±26.44 98.78 0.41 
For MEC 150 ng 120 ng 272.15±3.31 100.80 1.22 
150 ng 150 ng 299.29±2.73 99.76 0.91 
150 ng 180 ng 331.40±2.29 100.42 0.69 
c) 
 
Three independent analyses at each level; SD = standard deviation; RSD = relative standard deviation 
 Table 8: Results from robustness experiments 
Condition Value Mean % recovery  % RSD   Retardation factor (Rf)(d)±SD 
DUL MEC DUL MEC DUL MEC 
Mobile phase 
ratio 
Propanol: water: ammonia (8.5:2.5:1.0, v/v/v) 98.48 98.66 0.25 0.66 0.74±0.007 0.52±0.008 
Propanol: water: ammonia (9.5:1.5:1.0, v/v/v) 100.16 100.66 0.23 0.35 0.78±0.008 0.57±0.004 
Saturation time 15 min 99.75 99.52 0.47 0.55 0.73±0.008 0.52±0.007 
25 min 99.93 98.95 0.19 0.44 0.79±0.010 0.59±0.007 
d)
 
Average of three measurements at each condition; SD = standard deviation; RSD = relative standard deviation 
Robustness of the method 
By introducing small changes in the mobile phase composition and 
chamber saturation time in chromatographic conditions and the 
results were examined. There were very slight changes in the peak 
area and retardation factor. The lower value of SD and % RSD 
indicated the robustness of method (table 8). 
Analysis of duloxetine HCl and methylcobalamin formulation 
(capsule Duzela®
The validated method was used to estimate the DUL and MEC 
content of a commercially available brand of the capsule containing 
30 mg of DUL and 1.5 mg of MEC. Recovery of DUL and MEC from 
capsule formulation were 99.28% (RSD 0.73%) and 98.77% (RSD 
 M 30) 
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0.56%), respectively (table 9). The amounts measured were in good 
agreement with the label claims. The results of the assay indicated 
that the method was selective for analysis of DUL and MEC without 
interference from the excipients present (fig. 9). 
 
Table 9: Results obtained by the proposed method for the assay of drugs in pharmaceutical preparations (Duzela®
Parameter 
 M 30 capsules (label 
claim 30 mg DUL and 1.5 mg MEC); (n = 6)) 
DUL MEC 
Mean Peak Area 18449.33 1120.00 
Recovery (%) 99.28 98.77 
RSD (%) 0.73 0.56 
 RSD = relative standard deviation 
 
 
Fig. 9: Chromatogram of duloxetine HCl (Retardation factor (Rf): 0.77) and Methylcobalamin (Retardation factor (Rf
 
): 0.54) in marketed 
formulation 
CONCLUSION 
A simple, rapid, accurate, precise, specific and reproducible HPTLC 
analytical method with UV detection was developed for the 
determination of Duloxetine HCl and Methylcobalamin in active 
pharmaceutical ingredients and in marketed capsule dosage form. A 
Quality by Design (CCD design and response surface methodology) 
approach was successfully applied for optimization of HPTLC 
method for estimation of Duloxetine HCl and Methylcobalamin. First, 
the method goals were clarified based on process understanding. 
The experimental design described the scrutinizing of the key 
components including water content and saturation time. Their 
interrelationship was studied, and optimized condition was 
obtained. A better understanding of the factors influencing 
chromatographic separation and greater confidence in the ability of 
the method to meet their intended purpose was done. It gave good 
resolution between two peaks and reasonable retardation factors for 
both peaks. The obtained results indicate that the use of a CCD 
design and multi-criteria decision-making approach is a flexible 
procedure that can reduce the number of necessary experiments for 
the development and optimization of an HPTLC method. 
Furthermore, it is an economical method that can be used to 
generate a maximum amount of information in less time with a small 
number of experiments. The method was validated in accordance 
with ICH guidelines. The method seems to be suitable for the quality 
control in the pharmaceutical industry because of its high simplicity 
and reproducibility. 
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